HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Uzi Izhar Niv Ad Ehud Rudis Eli Milgalter Gideon Merin Amir Elami Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Izhar, U. Articles by Elami, A. Search for Related Content PubMed PubMed Citation Articles by Izhar, U. Articles by Elami, A. Related Collections Anesthesia Cardiac - pharmacology Coronary disease Electrophysiology - arrhythmias

J Thorac Cardiovasc Surg 2005;129:401-406
© 2005 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

When should we discontinue antiarrhythmic therapy for atrial fibrillation after coronary artery bypass grafting? A prospective randomized study

Department of Cardiothoracic Surgery, Hadassah University Hospital, Jerusalem, Israel

Received for publication March 17, 2004; revisions received June 10, 2004; accepted for publication June 28, 2004.

^* Address for reprints: Uzi Izhar, MD, Cardiothoracic Surgery Department, Hadassah University Hospital, Jerusalem 91120, Israel (E-mail: izharu{at}bezeqint.net).

BACKGROUND: New-onset atrial fibrillation after coronary artery bypass grafting is common. Medical therapy includes various antiarrhythmic drugs to control heart rate and restore sinus rhythm. The purpose of this study was to determine the duration of antiarrhythmic therapy after discharge from the hospital.

METHODS: One hundred twenty-nine patients in whom new atrial fibrillation after coronary artery bypass grafting developed and successfully reverted to sinus rhythm were prospectively randomized at dismissal to receive antiarrhythmic therapy for 1 week (group A; n = 44), 3 weeks (group B; n = 42), or 6 weeks (group C; n = 43). Patients were followed up for an additional 4 weeks after discontinuation of antiarrhythmic therapy for detection of recurrent atrial fibrillation.

RESULTS: The incidence of new atrial fibrillation during the study period was 21.2% (256/1206). Among the 129 patients who consented to the study, conversion to sinus rhythm was accomplished with the following medications: amiodarone (group A, 82%; group B, 93%; group C, 88%; P = .29), digoxin (group A, 16%; group B, 7%; group C, 7%; P = .29), ß-blockers (group A, 27%; group B, 19%; group C, 14%; P = .30), calcium channel blockers (group A, 2%; group B, 2%; group C, 0%; P = .60), quinidine (group A, 2%; group B, 2%; group C, 7%; P = .44), and procainamide (group A, 4.5%; group B, 2%; group C, 0%; P = .37). Follow-up was completed in 128 patients (99.2%). There was no significant difference in the recurrence of atrial fibrillation among groups (0%, 2%, and 0% for groups A, B, and C, respectively).

CONCLUSIONS: Patients with new atrial fibrillation after coronary artery bypass grafting, converted to normal sinus rhythm before hospital discharge, have a benign course. Antiarrhythmic therapy as short as 1 week may be appropriate in these patients.

This article has been cited by other articles:

				G. Buckberg Editorial comment: Left ventricular reconstruction for dilated ischemic cardiomyopathy: biology, registry, randomization, and credibility Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 759 - 761. [Full Text] [PDF]

				R. H. Jones The Year in Cardiovascular Surgery J. Am. Coll. Cardiol., May 16, 2006; 47(10): 2094 - 2107. [Full Text] [PDF]